CHARM Therapeutics , a 3D deep learning biotechnology company dedicated to the discovery and development of transformational medicines, announced the appointments of Sarah Skerratt, Ph.D. announced as Chief Scientific Officer (CSO) and Laura Hare as Chief People Officer and Head of Business Operations.
“These leadership team updates mark a transition period for CHARM. Sarah Skerratt’s promotion to CSO is a testament to her exceptional contribution to our pipeline and we are delighted to welcome Laura Hare, whose wealth of experience will be critical in our next phase of growth,” said Laksh Aithani, co-founder and CEO of CHARM Therapeutics.
The promotion of Dr. Sarah Skerratt’s appointment as CSO comes as CHARM’s pipeline makes significant progress under her leadership and expertise. Dr. Sarah Skerratt brings 20 years of experience in drug discovery and is a leader with an impressive track record of delivering results from the experimental phase through to clinical and diverse therapeutic areas. Her long tenure includes senior positions at Merck Sharp & Dohme, Vertex, Convergence/Biogen and Pfizer Inc., cementing her reputation in drug discovery and development. She is a trained organic chemist and holds a Ph.D. from the University of Nottingham and completed her habilitation studies at Stanford University as a Fulbright visiting scholar.
Laura Hare joins CHARM from F-star Therapeutics, where she held a leadership position as Senior Vice President of Corporate Operations and People and led the organization through multiple transformation phases – from early drug discovery to its successful acquisition of invoX Pharma. With 20 years of experience with high-growth and scale-up companies in both technology and biotechnology, her experience will be pivotal in leading CHARM’s rapid growth and fostering a thriving workplace culture. Laura Hare’s corporate operations and human resources experience is expected to play a significant role in CHARM’s strategy and operations management as the company continues to expand.
CHARM Therapeutics discovers and develops small molecule drugs against difficult-to-treat targets using its proprietary 3D deep learning platform, DragonFold. Supported by the first high-throughput protein-ligand co-folding algorithm and a world-class team of scientists and engineers, CHARM strives to provide innovative concepts to create life-changing therapies for patients.
Cambridge and London-based CHARM has raised $70 million in funding to date and is building an interdisciplinary and entrepreneurial team by bringing together AI and biotechnology leaders. It is backed by high-quality international investors including OrbiMed, F-Prime Capital, General Catalyst, Khosla Ventures, Bristol Myers Squibb, NVIDIA and grep -vc.
SOURCE: BusinessWire
